Hansa Biopharma AB (publ) (STO:HNSA)
32.08
-1.72 (-5.09%)
At close: Mar 2, 2026
Hansa Biopharma AB Employees
Hansa Biopharma AB had 125 employees as of December 31, 2025. The number of employees decreased by 10 or -7.41% compared to the previous year.
Employees
125
Change
-10
Growth
-7.41%
Revenue / Employee
1.78M SEK
Profits / Employee
-4.23M SEK
Market Cap
3.26B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 125 | -10 | -7.41% |
| Sep 30, 2025 | 133 | -2 | -1.48% |
| Jun 30, 2025 | 140 | -6 | -4.11% |
| Mar 31, 2025 | 138 | -28 | -16.87% |
| Dec 31, 2024 | 135 | -33 | -19.64% |
| Sep 30, 2024 | 135 | -33 | -19.64% |
| Jun 30, 2024 | 146 | -16 | -9.88% |
| Mar 31, 2024 | 166 | 7 | 4.40% |
| Dec 31, 2023 | 168 | 18 | 12.00% |
| Sep 30, 2023 | 168 | 23 | 15.86% |
| Jun 30, 2023 | 162 | 17 | 11.72% |
| Mar 31, 2023 | 159 | 18 | 12.77% |
| Dec 31, 2022 | 150 | 19 | 14.50% |
| Sep 30, 2022 | 145 | 18 | 14.17% |
| Jun 30, 2022 | 145 | 32 | 28.32% |
| Mar 31, 2022 | 141 | 40 | 39.60% |
| Dec 31, 2021 | 131 | 44 | 50.57% |
| Sep 30, 2021 | 127 | 47 | 58.75% |
| Jun 30, 2021 | 113 | 35 | 44.87% |
| Mar 31, 2021 | 101 | 23 | 29.49% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| BioInvent International AB | 124 |
| Diamyd Medical AB | 41 |
| Egetis Therapeutics AB | 40 |
| Vicore Pharma Holding AB | 36 |
| Genovis AB (publ.) | 36 |
| Saniona AB | 31 |
| Xspray Pharma AB | 26 |
| Cantargia AB | 22 |
Hansa Biopharma AB News
- 12 days ago - Hansa Biopharma's Biologics License Application (BLA) for imlifidase accepted by the FDA - PRNewsWire
- 19 days ago - Hansa Biopharma AB (publ) (HNSBF) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 19 days ago - Hansa Biopharma AB (STU:24H) Q4 2025 Earnings Call Highlights: Robust Revenue Growth and ... - GuruFocus
- 19 days ago - Q4 2025 Hansa Biopharma AB Earnings Call Transcript - GuruFocus
- 19 days ago - Hansa Biopharma AB (publ) 2025 Q4 - Results - Earnings Call Presentation - Seeking Alpha
- 19 days ago - Hansa Biopharma Reports Fourth Quarter and Full-Year 2025 Financial Results - PRNewsWire
- 5 weeks ago - Hansa Biopharma AB: Hansa Biopharma has won the 2025 SwedenBIO Award - Finanz Nachrichten
- 5 weeks ago - Hansa Biopharma has won the 2025 SwedenBIO Award - PRNewsWire